toxins Article Comparison of Preclinical Properties of Several Available Antivenoms in the Search for Effective Treatment of Vipera ammodytes and Vipera berus Envenoming Tihana Kurtovi´c 1,2,*,† , Maja Lang Balija 1,2,†, Miran Brvar 3,4, Mojca Dobaja Borak 3, Sanja Mateljak Lukaˇcevi´c 1,2 and Beata Halassy 1,2,* 1 Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, 10000 Zagreb, Croatia;
[email protected] (M.L.B.);
[email protected] (S.M.L.) 2 Centre of Excellence for Virus Immunology and Vaccines, CERVirVac, Rockefellerova 10, 10000 Zagreb, Croatia 3 Centre for Clinical Toxicology and Pharmacology, University Medical Centre Ljubljana, Zaloška Cesta 7, 1000 Ljubljana, Slovenia;
[email protected] (M.B.);
[email protected] (M.D.B.) 4 Centre for Clinical Physiology, Faculty of Medicine, University of Ljubljana, Zaloška Cesta 4, 1000 Ljubljana, Slovenia * Correspondence:
[email protected] (T.K.);
[email protected] (B.H.) † Equal contribution. Abstract: Snakebites are a relatively rare medical emergency in Europe. In more than half of the annual cases caused by Vipera ammodytes, Vipera berus, and Vipera aspis, immunotherapy with animal- derived antivenom is indicated. Among eight products recently identified as available against European medically relevant species, only Zagreb antivenom, Viperfav, and ViperaTAb have been 0 used almost exclusively for decades. Zagreb antivenom comprises V. ammodytes-specific F(ab )2 Citation: Kurtovi´c,T.; Lang Balija, 0 fragments. Viperfav is a polyspecific preparation based on F(ab )2 fragments against V. aspis, V. berus, M.; Brvar, M.; Dobaja Borak, M.; and V. ammodytes venoms.